North America Metagenomics Market 2027 By Product, Application and Country

The North America Metagenomics market is expected to reach US$ 106.9 Mn in 2027 from US$ 55.2 Mn in 2018. The market is estimated to grow with a CAGR of 8.0% from 2018-2027.

The growth of the market is driven by the factors such as increasing investments in the metagenomics and diverse applications of metagenomics, in the North America region. Whereas, high cost associated with metagenomics is likely to have a negative impact on the growth of the market in the coming years.

Metagenomics is the upcoming field of the biotechnology and the extensive researches are being conducted in the labs across the world. Several clinical labs in United States, have already undertaken the considerable lengths to upgrade and validate a wide range of protocols for agnostically detecting viral, bacterial, fungal and eukaryotic parasite nucleic acid in different specimens of patient to benefit in diagnosis for particularly intractable cases.

The extensive research need is pushing the venture capitals or academic medical centers to subsidize the prices for the metagenomics testing. They help to conduct researches to carry out testing in US$ 2000 - US$ 3000 per sample.

Major market players such as Illumina based in California have introduced breakthrough technologies that have enabled in the cost and time reduction in the sequencing. For instance, Illumina’s NovaSeq 6000 Sequencing System releases groundbreaking innovations. The system enables accessible throughput and flexibility for virtually any sequencing method, genome and scale of project.

Owing to factor that the cost of the metagenomics is been subsidize by the venture capitalists and the innovative technology by the market leaders that enables the access to the metagenomics studies are likely to propel the growth of the market in the forecast period.

US is anticipated to lead the adoptions of Metagenomics across the North American region through the forecast period. The major players headquartered in the US are also focused towards developing innovative and novel products and bringing them into market, which is also one of the major factors driving the growth of US in the North America metagenomics market. Moreover, the companies are significantly investing under research and development to come-up with medical products that are derived from natural microbial sources. For instance, in August 2018, Genentech and Lodo initiated a US$ 1 Bn project to develop unique, natural products from the microbial DNA found in soil. Under the collaboration, Genentech will use Lodo’s metagenome-prospecting platform to identify novel small molecules with the potential for treating disease.

Mexico Metagenomics Market Revenue and Forecasts to 2027 (US$ Bn)

NORTH AMERICA METAGENOMICS - MARKET SEGMENTATION

By Product

Instruments & Software
Consumables

NORTH AMERICA METAGENOMICS - MARKET SEGMENTATION

By Application

Clinical Diagnostics
Drug Discovery

By Country

U.S.
Canada
Mexico

Companies Mentioned

Merck KGaA
Thermo Fisher Scientific Inc.
Agilent Technologies
Qiagen
Bio-Rad Laboratories, Inc.
Perkinelmer Inc.
Illumina Inc.
F Hoffman-La Roche Ltd.
Oxford Nanopore Technologies Ltd.
Pacific Bioscience of California, Inc.

North America Metagenomics Strategic Insights

Strategic insights for the North America Metagenomics provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

strategic-framework/north-america-metagenomics-market-strategic-framework.webp

Get more information on this report

North America Metagenomics Report Scope

Report Attribute	Details
Market size in 2018	US$ 55.2 Million
Market Size by 2027	US$ 106.9 Million
Global CAGR (2018 - 2027)	8.0%
Historical Data	2016-2017
Forecast period	2019-2027
Segments Covered	By Product Instruments & Software and Consumables By Application Clinical Diagnostics Drug Discovery Metagenomics
Regions and Countries Covered	North America US Canada Mexico
Market leaders and key company profiles	Merck KGaA Thermo Fisher Scientific Inc. Agilent Technologies Qiagen Bio-Rad Laboratories, Inc. Perkinelmer Inc. Illumina Inc. F Hoffman-La Roche Ltd. Oxford Nanopore Technologies Ltd. Pacific Bioscience of California, Inc.

Get more information on this report

North America Metagenomics Regional Insights

The geographic scope of the North America Metagenomics refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.